ArticleMayo Clinic proceedings2012
Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population.
Article in Mayo Clinic proceedings, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 135 citations in OpenAlex.
- Performance of hemodialysis with novel medium cut-off dialyzers.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Trial
- CleanSurvival: automated data preprocessing for time-to-event models using reinforcement learning.BMC medical informatics and decision making · 2026Article
- Quantum Computing in a Diagnostic-First Quantum Residual Boosting Framework for Clinical Survival Analysis in Oncology and Cardiology.Journal of clinical medicine · 2026Article
- The NF-κB Signalling Pathway: Mechanisms, Consequences and Therapeutic Targets.Journal of cellular and molecular medicine · 2026Review
- Expert-Driven Survival Machines: Improving Stratification and Interpretability in Multiple Clinical Cohorts.ACM-BCB ... ... : the ... ACM Conference on Bioinformatics, Computational Biology and Biomedicine. ACM Conference on Bioinformatics, Computational Biology and Biomedicine · 2026Article
- Immunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.Future science OA · 2025Article
- CoxKAN: Kolmogorov-Arnold networks for interpretable, high-performance survival analysis.Bioinformatics (Oxford, England) · 2025Article
- Associations of serum total light chain kappa and lambda levels with all-cause mortality in Chinese centenarians.Immunity & ageing : I & A · 2025Article
- Leveraging the variational Bayes autoencoder for survival analysis.Scientific reports · 2024Article
- Case-Base Neural Network: Survival analysis with time-varying, higher-order interactions.Machine learning with applications · 2024Article
- Optimal Sparse Survival Trees.Proceedings of machine learning research · 2024Article
- Adaptive Discretization for Event PredicTion (ADEPT).Proceedings of machine learning research · 2024Article
- Effects of aerobic and resistance exercise for 9 months on serum free light chains in type 2 diabetes.Frontiers in physiology · 2024Article
- Maximum Likelihood Estimation of Flexible Survival Densities with Importance Sampling.Proceedings of machine learning research · 2023Article
- Calibration and Uncertainty in Neural Time-to-Event Modeling.IEEE transactions on neural networks and learning systems · 2023Article
- Insights into the Roles of B Cells in Patients with Sepsis.Journal of immunology research · 2023Review
- Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease.European cardiology · 2023Review
- Combined serum free light chain predicts prognosis in acute kidney injury following cardiovascular surgery.Renal failure · 2022Article
- Free Light Chains, High Mobility Group Box 1, and Mortality in Hemodialysis Patients.Journal of clinical medicine · 2022Article
- Novel Biomarkers of Inflammation for the Management of Diabetes: Immunoglobulin-Free Light Chains.Biomedicines · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveTo determine whether the free light chain (FLC) assay provides prognostic information relevant to the general population.
methodsAfter excluding persons with a known plasma cell disorder, we studied 15,859 Olmsted County, Minnesota, residents 50 years or older in whom unmasked data and samples for FLC testing were available. Baseline information was obtained between March 13, 1995, and November 21, 2003, and follow-up status and cause of death were identified through June 30, 2009. The κ and λ FLC sum (Σ FLC) was evaluated for its ability to predict overall survival. Specific causes of death were also investigated.
resultsIn 158,003 person-years of follow-up, 4348 individuals died. A high Σ FLC was significantly predictive of worse overall survival; the risk ratio for death for those with the highest decile of Σ FLC (ie, ≥ 4.72 mg/dL) was 4.4 (95% confidence interval, 4.1-4.7) relative to the remaining study participants. Multivariate analyses demonstrated that this excess risk of death was independent of age, sex, and renal insufficiency, with a corrected risk ratio of 2.1 (95% confidence interval, 1.9-2.2). The increased mortality was not restricted to any particular cause of death because the observed-to-expected risk of death from most causes was significantly higher among those individuals with an antecedent Σ FLC of 4.72 mg/dL or higher, which is near the upper limit of normal for the test.
conclusionA nonclonal elevation of Σ FLC is a significant predictor of worse overall survival in the general population of persons without plasma cell disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.